Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8529 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD8529 40 mg |
| 2 | PLACEBO_COMPARATOR | Placebo |
| 3 | OTHER | Risperidone 4 mg (2mg on Day 1) |
| Name | Type | Description |
|---|---|---|
| AZD 8529 | DRUG | 40mg oral daily capsule administered as a single dose in the morning for 28 days |
| Risperidone | DRUG | 4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days |
| Placebo to match AZD8529 | DRUG | Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period |
| Placebo to match risperidone | DRUG | Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period |
| AZD8529 | DRUG | 2 capsules by mouth for 3 days |
Inclusion Criteria: * Patient will need to read, understand and sign an informed consent prior to any study specific procedures * Patient will have certain schizophrenia symptoms deemed by the investigator as appropriate for the study entry Exclusion Criteria: * Patients will be excluded based on...
Top 15 of 16 competitors
AZD8529 is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for neurological conditions. It has been studied in schizophrenia and in memory impairment, including ketamine-induced working memory impairment in healthy volunteers. It is a Phase 1 stage asset and is not described as approved.
AZD8529 has been studied for schizophrenia, including effects on cognition and negative symptoms. A completed Phase 2 trial, NCT00921804, assessed efficacy, safety, and tolerability in 296 adult schizophrenia patients, and a completed Phase 1 trial, NCT00986531, examined cognition and negative symptoms in 59 patients.
AZD8529 is developed by AstraZeneca PLC, which trades under the ticker AZN. The company sponsored the clinical trials of the compound in schizophrenia and memory impairment conducted in the United States.
AZD8529 is in Phase 1 development overall. Its trial record includes two completed Phase 1 studies, NCT00986531 and NCT00985933, plus a completed Phase 2 study, NCT00921804. No trials are currently listed as active, and the compound is investigational rather than approved.
AZD8529 has been evaluated in three completed trials: NCT00986531 in schizophrenia, NCT00985933 in healthy volunteers with ketamine-induced working memory impairment, and NCT00921804 in adult schizophrenia patients. Total enrollment across these studies was 355 participants, and the trials used randomized, double-blind, placebo-controlled designs.
Yes, AZD8529 and AZD 8529 refer to the same investigational compound from AstraZeneca PLC. The spacing differs only in how the code name is written, so searches for either form point to the same small molecule studied in schizophrenia and memory impairment.